Raymond James raises Royal Gold stock price target to $264 on streaming model

Shift4 Payments has faced a setback as Raymond James has lowered its stock price target following mixed financial results. This adjustment reflects concerns about the company's performance and could impact investor confidence. Understanding these changes is crucial for stakeholders as they navigate the evolving landscape of the payments industry.

Royal Gold reported record revenue for Q3 2025, showcasing the company's strong performance in the gold sector. However, it fell short of earnings per share (EPS) expectations, which has raised some concerns among investors. This news is significant as it highlights the challenges companies face in balancing revenue growth with profitability, especially in fluctuating markets.

Backblaze's stock price target has been lowered to $10.50 by Raymond James, reflecting concerns about the company's growth outlook in the B2 sector. This adjustment is significant as it indicates potential challenges for Backblaze in meeting investor expectations, which could impact its market performance and investor confidence.

Morgan Stanley has raised its price target for Raymond James stock from $184 to $185, reflecting confidence in the company's performance and potential growth. This slight increase indicates that analysts believe Raymond James is on a positive trajectory, which could encourage investors and boost market sentiment around the stock.

Cameco's stock rating has been reiterated as 'Outperform' by Raymond James, signaling strong confidence in the company's future performance. This endorsement is significant as it reflects the analysts' belief in Cameco's potential for growth, particularly in the uranium market, which is gaining attention due to increasing demand for clean energy sources. Investors may find this news encouraging as it suggests that Cameco is well-positioned to capitalize on upcoming opportunities.

Raymond James has expressed concerns regarding AT&T's recent announcement, viewing it as a negative development for Cogent's stock performance. This is significant as it highlights the potential impact of major telecom decisions on smaller companies in the industry, suggesting that investors should be cautious about Cogent's future prospects.

Raymond James has reaffirmed its 'Strong Buy' rating on Biohaven stock, even in light of recent setbacks. This endorsement highlights the firm's confidence in Biohaven's long-term potential and suggests that investors might find value despite current challenges. Such a strong recommendation can influence market perceptions and encourage investment in Biohaven, which is crucial for its growth and innovation in the pharmaceutical sector.

Sionna Therapeutics has received a strong buy rating from Raymond James, indicating confidence in the company's future performance. This endorsement is significant as it suggests that analysts believe Sionna's stock is undervalued and poised for growth, which could attract more investors and boost market interest. Such positive ratings can lead to increased trading activity and potentially higher stock prices, making it an important development for current and prospective shareholders.